RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
-8.99%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$798M
AUM Growth
+$798M
(-12%)
Cap. Flow
-$2.7M
Cap. Flow
% of AUM
-0.34%
Top 10 Holdings %
Top 10 Hldgs %
29.72%
Holding
97
New
9
Increased
24
Reduced
42
Closed
4
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$27.9M |
| 2 |
Merck
MRK
|
$18.1M |
| 3 |
AbbVie
ABBV
|
$12.9M |
| 4 |
Esperion Therapeutics
ESPR
|
$8.94M |
| 5 |
Nektar Therapeutics
NKTR
|
$8.65M |
Top Sells
| 1 |
Horizon Bancorp
HBNC
|
$26.2M |
| 2 |
Humana
HUM
|
$11.5M |
| 3 |
Incyte
INCY
|
$8.5M |
| 4 |
HCA Healthcare
HCA
|
$7.37M |
| 5 |
Elevance Health
ELV
|
$7.2M |
Sector Composition
| 1 | Healthcare | 92.7% |
| 2 | Industrials | 0.42% |
| 3 | Technology | 0.13% |
| 4 | Financials | 0.1% |
| 5 | Energy | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
GTHX
26
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $12.2M | 1.53% |
535,657
+261,383
| +95% | +$5.95M |
|
27
Cigna
CI
$80.2B
| $12.1M | 1.52% |
80,000
-16,191
| -17% | -$2.46M |
|
|
IMMU
28
DELISTED
Immunomedics Inc
IMMU
| $11.3M | 1.41% |
850,000
-1,367
| -0.2% | -$18.1K |
|
29
Thermo Fisher Scientific
TMO
$183B
| $11.1M | 1.39% |
38,000
+8,200
| +28% | +$2.39M |
|
30
FibroGen
FGEN
$48.4M
| $10.9M | 1.37% |
11,800
-2,098
| -15% | -$1.94M |
|
|
MYOK
31
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $10.4M | 1.31% |
200,000
-25,024
| -11% | -$1.31M |
|
32
Xencor
XNCR
$594M
| $10.2M | 1.28% |
302,523
-17,269
| -5% | -$582K |
|
33
MacroGenics
MGNX
$121M
| $10.2M | 1.28% |
799,373
-57,796
| -7% | -$737K |
|
34
Exact Sciences
EXAS
$9.33B
| $9.74M | 1.22% |
107,786
+17,786
| +20% | +$1.61M |
|
35
Iovance Biotherapeutics
IOVA
$800M
| $9.46M | 1.19% |
520,000
-230,700
| -31% | -$4.2M |
|
|
AERI
36
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $9.13M | 1.14% |
475,000
+215,000
| +83% | +$4.13M |
|
|
37
HCA Healthcare
HCA
$95.4B
| $9.03M | 1.13% |
75,000
-61,164
| -45% | -$7.37M |
|
38
LivaNova
LIVN
$3.09B
| $8.86M | 1.11% |
120,000
-30,000
| -20% | -$2.21M |
|
39
Cencora
COR
$57.2B
| $8.15M | 1.02% |
99,000
-42,520
| -30% | -$3.5M |
|
40
Edwards Lifesciences
EW
$47.7B
| $8.05M | 1.01% |
109,755
+15,000
| +16% | +$1.1M |
|
41
Agios Pharmaceuticals
AGIO
$2.36B
| $7.94M | 1% |
245,002
+45,002
| +23% | +$1.46M |
|
|
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.79M | 0.98% |
100,000
-82,008
| -45% | -$6.39M |
|
|
MDCO
43
DELISTED
Medicines Co
MDCO
| $7.65M | 0.96% |
153,000
-47,000
| -24% | -$2.35M |
|
44
Centene
CNC
$14.8B
| $7.57M | 0.95% |
175,000
-120,000
| -41% | -$5.19M |
|
|
ARNA
45
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $7.09M | 0.89% |
155,000
-15,000
| -9% | -$687K |
|
46
Sangamo Therapeutics
SGMO
$161M
| $6.65M | 0.83% |
734,811
-59,146
| -7% | -$535K |
|
47
Omnicell
OMCL
$1.51B
| $6.5M | 0.82% |
90,000
-10,375
| -10% | -$750K |
|
|
ITCI
48
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.35M | 0.8% |
850,000
-99,833
| -11% | -$746K |
|
|
AMRN
49
Amarin Corp
AMRN
$311M
| $6.06M | 0.76% |
20,000
+2,460
| +14% | +$746K |
|
50
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| $5.88M | 0.74% |
290,000
-100,000
| -26% | -$2.03M |
|